2 Red Flags for Ocugen's Future
Although things have improved, we are still in the midst of a pandemic. One important reason we are getting closer to some sort of pre-pandemic normal is that vaccines for the disease are now widely available in many countries. Still, we can never have too many safe and effective vaccines, and several companies are looking to launch new ones on the market.
Ocugen (NASDAQ: OCGN), a clinical-stage biotech that focuses on eye-related diseases, is one such company aiming to make a dent in the coronavirus vaccine market in North America. However, the company has faced multiple headwinds, and there are more obstacles investors have to consider when it comes to this biotech. Let's look into two such issues and discuss whether Ocugen is worth investing in.
Image source: Getty Images.
Source Fool.com
